Jacobs Levy Equity Management’s Syros Pharmaceuticals, Inc. Common Stock SYRS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q2 | – | Sell |
-8,881
| Closed | -$106K | – | 1108 |
|
|
2022
Q1 | $106K | Sell |
8,881
-1,450
| -14% | -$17.3K | ﹤0.01% | 981 |
|
|
2021
Q4 | $337K | Buy |
10,331
+166
| +2% | +$5.42K | ﹤0.01% | 886 |
|
|
2021
Q3 | $454K | Buy |
10,165
+5,909
| +139% | +$264K | ﹤0.01% | 876 |
|
|
2021
Q2 | $232K | Sell |
4,256
-2,055
| -33% | -$112K | ﹤0.01% | 968 |
|
|
2021
Q1 | $472K | Sell |
6,311
-5,949
| -49% | -$445K | ﹤0.01% | 867 |
|
|
2020
Q4 | $1.33M | Buy |
12,260
+6,151
| +101% | +$667K | 0.01% | 660 |
|
|
2020
Q3 | $540K | Sell |
6,109
-633
| -9% | -$56K | 0.01% | 774 |
|
|
2020
Q2 | $719K | Buy |
6,742
+336
| +5% | +$35.8K | 0.01% | 727 |
|
|
2020
Q1 | $380K | Buy |
6,406
+1,884
| +42% | +$112K | ﹤0.01% | 792 |
|
|
2019
Q4 | $312K | Buy |
+4,522
| New | +$312K | ﹤0.01% | 850 |
|
|
2019
Q2 | – | Sell |
-1,628
| Closed | -$149K | – | 1048 |
|
|
2019
Q1 | $149K | Sell |
1,628
-8,618
| -84% | -$789K | ﹤0.01% | 921 |
|
|
2018
Q4 | $571K | Buy |
10,246
+2,360
| +30% | +$132K | 0.01% | 712 |
|
|
2018
Q3 | $939K | Buy |
7,886
+220
| +3% | +$26.2K | 0.01% | 660 |
|
|
2018
Q2 | $783K | Buy |
+7,666
| New | +$783K | 0.01% | 716 |
|
|
2018
Q1 | – | Sell |
-1,717
| Closed | -$167K | – | 1074 |
|
|
2017
Q4 | $167K | Buy |
+1,717
| New | +$167K | ﹤0.01% | 928 |
|